DDAVP'S Shortening of the Bleeding Time Seems Due to Plasma von Willebrand Factor

Abstract

The pathomechanism of desmopressin (DDAVP) dependent shortening of the acetylsalicylic acid (ASA) prolonged bleeding time (BT) is still unclear. The mechanism of action is supposed to be related to the plasma levels of von Willebrand factor (vWf), but a platelet effect is also discussed. We tried to investigate whether this effect of DDAVP might be due to either plasma vWF or platelets or both. We measured the effect of DDAVP (0.4 μg/ml bw in 250 ml 0.9% NaCI) on the Thrombostat 4000 (in vitro bleeding test (IVBT)) after each of 16 volunteers ingested 100 mg of ASA twice. To measure the possible effect ofDDAVP on plasma and platelets separately, a mixture of 800 μl of platelet poor plasma (PPP) or 200 μl of isolated platelets after DDAVP, respectively, was prepared and the IVBT monitored. Two hundred μl of PPP or platelets, respectively, served as a control. In an additional experiment, vWF concentrate (12 Vlml) dissolved in 200 μl of PPP after ASA ingestion, as described above, was added to 800 μl of citrated whole blood from the same volunteers.

The addition of PPP after DDAVP as well as the PPP or PRP after ASA enriched with vWf led to a significant shortening of the IVBT in comparison to the control, indicating that the effect of DDAVP on the prolonged BT seems to be an isolated effect of plasma vWf. By adding platelets we were not able to show a direct effect of DDAVP on platelets.

Keywords

DDAVP - bleeding time - von Willebrand factor - platelets - Thrombostat - acetylsalicylic acid

• References

• 1 Mannucci PM. Desmopressin: A nontransfusional hemostatic agent. Annu Rev Med 41: 55-64 1990;
• 2 Lethagen ST, Rugam P. The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetylsalicylic acid intake in healthy volunteers. Thromb Haemost 67: 185-186 1992;
• 3 Escolar G, Cases A, Monteagudo J, Garrido M, Lopez J, Ordinas A, Revert L, Castillo R. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 114: 36-42 1989;
• 4 Cattaneo M, Moia M, Della Valle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 74: 1972-1975 1989;
• 5 Yang X, Disa J, Rao K. Effect of 1-Desamino-8-D-Arginine-Vasopressin (DDAVP) on human platelets. Thromb Res 59: 809-818 1990;
• 6 Dietrich G, Weber D, Kretschmer V. In-vitro bleeding test: Standardization of the methodical procedure. Lab Med 17: 317-323 1993;
• 7 Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin. Blood 71: 1366-1374 1988;
• 8 O'Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: Filter blockage and the long bleeding time in von Willebrand's disease. Blood 70: 1354-1361 1987;
• 9 Lethagen ST. DDAVP-induced enhancement of platelet retention: Its dependence on platelet von Willebrand factor and the platelet receptor GP lIb/lIla. In: Lethagen ST, (ed.) DDAVP (Desmopressin) and Hemostasis. . Lidbergs Blankett AB; Malmö, Sweden: 1992: 66-70